Amneal Pharmaceuticals (AMRX) Total Non-Current Liabilities (2017 - 2026)
Amneal Pharmaceuticals (AMRX) posted quarterly Total Non-Current Liabilities of $2.8 billion for Q1 2026, up 18.03% year-over-year from $2.3 billion in Q1 2025, and down 0.66% quarter-over-quarter from $2.8 billion in Q4 2025.
Amneal Pharmaceuticals (AMRX) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Amneal Pharmaceuticals' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $2.8 billion for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 18.03% year-over-year to $2.8 billion; the TTM figure through Mar 2026 stood at $2.8 billion (up 18.03% YoY), while the FY2025 annual figure was $2.8 billion, up 15.5% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $2.8 billion, down from $2.8 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $2.9 billion in Q1 2022, with the low at $2.3 billion in Q1 2025.
- The 5-year median for Total Non-Current Liabilities is $2.7 billion (2023), against an average of $2.7 billion.
- The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities decreased 12.44% in 2024, then gained 18.03% in 2026.
- Amneal Pharmaceuticals' Total Non-Current Liabilities stood at $2.8 billion in 2022, then fell by 9.62% to $2.6 billion in 2023, then dropped by 5.79% to $2.4 billion in 2024, then gained by 15.5% to $2.8 billion in 2025, then slipped by 0.66% to $2.8 billion in 2026.
- Business Quant data shows AMRX's Total Non-Current Liabilities at $2.8 billion in Q1 2026, $2.8 billion in Q4 2025, and $2.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Amneal Pharmaceuticals | 5.70 Bn | 5.57 Bn | 334.51 Mn | 2.78 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.78 Bn |
| Mar 31, 2026 | 2.77 Bn |
| Dec 31, 2025 | 2.79 Bn |
| Sep 30, 2025 | 2.78 Bn |
| Jun 30, 2025 | 2.36 Bn |
| Mar 31, 2025 | 2.35 Bn |
| Dec 31, 2024 | 2.42 Bn |
| Sep 30, 2024 | 2.40 Bn |
| Jun 30, 2024 | 2.40 Bn |
| Mar 31, 2024 | 2.64 Bn |
| Dec 31, 2023 | 2.56 Bn |
| Sep 30, 2023 | 2.74 Bn |
| Jun 30, 2023 | 2.74 Bn |
| Mar 31, 2023 | 2.76 Bn |
| Dec 31, 2022 | 2.84 Bn |
| Sep 30, 2022 | 2.84 Bn |
| Jun 30, 2022 | 2.86 Bn |
| Mar 31, 2022 | 2.86 Bn |
| Dec 31, 2021 | 2.88 Bn |
| Sep 30, 2021 | 2.91 Bn |